Active Biotech Q2 2023: New Focus on Myelofibrosis - Redeye

Active Biotech will move the focus of the clinical development of tasquinimod to myelofibrosis, which is an indication with a high unmet need and little competition. The overall strategy will be to continue relying on partners for the clinical development of all assets.

Länk till analysen i sin helhet: https://www.redeye.se/research/938081/active-biotech-q2-2023-new-focus-on-myelofibrosis?utm_source=finwire&utm_medium=RSS